ALBANY, N.Y., Nov. 29, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) announced today that it has entered into a multi-year supply agreement for an undisclosed product with Shire US Manufacturing, Inc. which product has been in AMRI's portfolio through the required stages of development. Shire plc, is a leading global biotechnology company focused on developing and marketing innovative medicines for patients with rare diseases and other highly specialized conditions. The terms of the agreement are confidential. This is the second such multi-year agreement between AMRI and Shire, as AMRI has also been supplying a key neuroscience product to Shire.
"This agreement builds on the long-standing development and manufacturing relationship between Shire and AMRI," said William S. Marth, President and CEO of AMRI. "This long term contract with Shire illustrates our global and growing integrated API contract manufacturing business well and we look forward to continuing our relationship."
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP), and Fine Chemicals. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amri-announces-api-supply-agreement-with-shire-300368811.html